SCHOFIELD, Wis., Oct. 13, 2009 (GLOBE NEWSWIRE) -- PuraMed BioScience (OTCBB:PMBS), a pharmaceutical company engaged in the development and marketing of a line of revolutionary, new, non-prescription medicines that treat migraine headaches, insomnia and tension-type headaches under the brand name LipiGesic(TM), announced today that it has recently secured funding in excess of $325,000 which has allowed the Company to further efforts to reach its goals and objectives.
PuraMed's funding was provided by a number of investors during the past several months, many who invested as a direct result of sampling the LipiGesic(TM) M product and discovering its high level of efficacy in treating migraine headaches.
This funding has allowed the Company to build the initial retail inventory of LipiGesic(TM) M, and to further the patent application and approval process.
In addition, funding has enabled PuraMed BioScience to complete the production of the Company's first direct response television commercial, expected to begin airing in the fourth quarter of 2009. PuraMed is also updating its web capabilities to now include a comprehensive investor section, as well as building an e-commerce component which will allow for convenient purchase and free trials of the LipiGesic(TM) M product and all future products under the LipiGesic(TM) brand name.
Due to this recent investment, PuraMed has hired an investor relations firm, Investor Awareness, Inc. (www.investorawareness.com) and a public relations firm, North Shore Public Relations, Inc. (www.northshorepr.com) which are introducing the Company to key financial and business contacts, taking the Company's management on a national financial road show to present the Company's story for investment consideration, managing corporate communications, conducting media relations and launching a social media campaign to further raise awareness of the LipiGesic(TM) brand name.
"Our successful fundraising efforts continue to allow us to pursue many initiatives that have furthered our work in launching our first product, LipiGesic(TM) M, on a national level," said PuraMed BioScience CEO Russell Mitchell. "We are now in a position to solidify our relationships with key organizations within the medical community and to move forward with our business plan to bring to market effective, affordable, non-prescription solutions for migraine headaches and other ailments."
About the Company:
PuraMed BioScience, Inc. engages in the research, development and marketing of non-prescription medicinal and healthcare products. In addition to its leading product LipiGesic(TM) M, which provides acute relief from migraine headaches; the Company also has plans to launch LipiGesic(TM) PM that provides a remedy for insomnia and other sleep disorders as well as LipiGesic(TM) H for common tension headaches. For more information on PuraMed, visit the Company website at www.PuraMedBioScience.com, join the Company's group page on Facebook by searching "PuraMed BioScience" and follow the Company on Twitter at www.twitter.com/puramed.
Forward Looking Statements:
This news release contains forward-looking statements regarding PuraMed BioScience and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.